CD274 and non-small cell lung carcinoma: In 2018, Niemeijer et al. [60] reported the first-in-human study using whole-body PET imaging with [89Zr]nivolumab (anti-PD-1) and [18F]BMS-986192, an [18F]labeled anti-PD-L1 fibronectin-based protein (adnectin), in 13 patients with advanced NSCLC before treatment with nivolumab.